Progyny Reports 16.5% Q1 Revenue Growth, Raises 2025 Guidance

Progyny, a fertility and family building benefits company, reported a strong first quarter for 2025, beating both earnings and revenue expectations with adjusted EPS of $0.48 versus the consensus estimate of $0.45, and revenue rising 16.5% year-over-year to $324 million. The company also raised its full-year revenue guidance to between $1.185 billion and $1.235 billion, and increased its adjusted EPS guidance to $1.59, reflecting confidence in continued growth. Progyny's CEO highlighted the company's progress in expanding its platform and maintaining its leadership position in women's health and family building solutions. The stock has significantly outperformed the market this year, gaining about 35.8%, supported by strong fundamentals and positive analyst sentiment, with an average price target implying a further 16.76% upside. Key financial indicators such as operating cash flow and free cash flow margins improved substantially, underscoring operational strength. Analysts continue to rate Progyny favorably, with a consensus 'Outperform' recommendation and robust long-term revenue growth of 35.7% annually over the past five years.